Allogeneic transplantation for advanced leukemia: Improved short-term outcome with blood stem cell grafts and tacrolimus

Donna Przepiorka, Cindy Ippoliti, Issa Khouri, Paolo Anderlini, Rakesh Mehra, Sergio Giralt, James Gajewski, Herbert Fritsche, Albert B. Deisseroth, Karen Cleary, Richard Champlin, Koen Van Besien, Borje Andersson, Martin Korbling

Research output: Contribution to journalArticle

41 Citations (Scopus)

Abstract

We have evaluated the use of blood stem cell grafts for rapid hematopoietic recovery and tacrolimus (FK506) as GVHD prophylaxis to reduce early mortality after allogeneic transplantation. Eighty-five adults with advanced leukemia received high-dose thiotepa, busulfan, and cyclophosphamide as a preparative regimen in a prospective Phase II study. All donors were HLA-matched and related. Marrow (BMT) was used for 44 patients and filgrastim-mobilized blood stem cells (SCT) for 41 patients. GVHD prophylaxis consisted of cyclosporine (CsA) or FK506 with methotrexate (MTX) or methylprednisolone (MP). The median time to neutrophil recovery was earlier after SCT than after BMT (day 10 vs. 17, P

Original languageEnglish (US)
Pages (from-to)1806-1810
Number of pages5
JournalTransplantation
Volume62
Issue number12
DOIs
StatePublished - Dec 27 1996
Externally publishedYes

Fingerprint

Homologous Transplantation
Tacrolimus
Blood Cells
Leukemia
Stem Cells
Transplants
Thiotepa
Busulfan
Methylprednisolone
Methotrexate
Cyclophosphamide
Cyclosporine
Neutrophils
Bone Marrow
Tissue Donors
Mortality

ASJC Scopus subject areas

  • Transplantation
  • Immunology

Cite this

Przepiorka, D., Ippoliti, C., Khouri, I., Anderlini, P., Mehra, R., Giralt, S., ... Korbling, M. (1996). Allogeneic transplantation for advanced leukemia: Improved short-term outcome with blood stem cell grafts and tacrolimus. Transplantation, 62(12), 1806-1810. https://doi.org/10.1097/00007890-199612270-00022

Allogeneic transplantation for advanced leukemia : Improved short-term outcome with blood stem cell grafts and tacrolimus. / Przepiorka, Donna; Ippoliti, Cindy; Khouri, Issa; Anderlini, Paolo; Mehra, Rakesh; Giralt, Sergio; Gajewski, James; Fritsche, Herbert; Deisseroth, Albert B.; Cleary, Karen; Champlin, Richard; Van Besien, Koen; Andersson, Borje; Korbling, Martin.

In: Transplantation, Vol. 62, No. 12, 27.12.1996, p. 1806-1810.

Research output: Contribution to journalArticle

Przepiorka, D, Ippoliti, C, Khouri, I, Anderlini, P, Mehra, R, Giralt, S, Gajewski, J, Fritsche, H, Deisseroth, AB, Cleary, K, Champlin, R, Van Besien, K, Andersson, B & Korbling, M 1996, 'Allogeneic transplantation for advanced leukemia: Improved short-term outcome with blood stem cell grafts and tacrolimus', Transplantation, vol. 62, no. 12, pp. 1806-1810. https://doi.org/10.1097/00007890-199612270-00022
Przepiorka, Donna ; Ippoliti, Cindy ; Khouri, Issa ; Anderlini, Paolo ; Mehra, Rakesh ; Giralt, Sergio ; Gajewski, James ; Fritsche, Herbert ; Deisseroth, Albert B. ; Cleary, Karen ; Champlin, Richard ; Van Besien, Koen ; Andersson, Borje ; Korbling, Martin. / Allogeneic transplantation for advanced leukemia : Improved short-term outcome with blood stem cell grafts and tacrolimus. In: Transplantation. 1996 ; Vol. 62, No. 12. pp. 1806-1810.
@article{838869d3edf64611bd76ce93ebb7a40e,
title = "Allogeneic transplantation for advanced leukemia: Improved short-term outcome with blood stem cell grafts and tacrolimus",
abstract = "We have evaluated the use of blood stem cell grafts for rapid hematopoietic recovery and tacrolimus (FK506) as GVHD prophylaxis to reduce early mortality after allogeneic transplantation. Eighty-five adults with advanced leukemia received high-dose thiotepa, busulfan, and cyclophosphamide as a preparative regimen in a prospective Phase II study. All donors were HLA-matched and related. Marrow (BMT) was used for 44 patients and filgrastim-mobilized blood stem cells (SCT) for 41 patients. GVHD prophylaxis consisted of cyclosporine (CsA) or FK506 with methotrexate (MTX) or methylprednisolone (MP). The median time to neutrophil recovery was earlier after SCT than after BMT (day 10 vs. 17, P",
author = "Donna Przepiorka and Cindy Ippoliti and Issa Khouri and Paolo Anderlini and Rakesh Mehra and Sergio Giralt and James Gajewski and Herbert Fritsche and Deisseroth, {Albert B.} and Karen Cleary and Richard Champlin and {Van Besien}, Koen and Borje Andersson and Martin Korbling",
year = "1996",
month = "12",
day = "27",
doi = "10.1097/00007890-199612270-00022",
language = "English (US)",
volume = "62",
pages = "1806--1810",
journal = "Transplantation",
issn = "0041-1337",
publisher = "Lippincott Williams and Wilkins",
number = "12",

}

TY - JOUR

T1 - Allogeneic transplantation for advanced leukemia

T2 - Improved short-term outcome with blood stem cell grafts and tacrolimus

AU - Przepiorka, Donna

AU - Ippoliti, Cindy

AU - Khouri, Issa

AU - Anderlini, Paolo

AU - Mehra, Rakesh

AU - Giralt, Sergio

AU - Gajewski, James

AU - Fritsche, Herbert

AU - Deisseroth, Albert B.

AU - Cleary, Karen

AU - Champlin, Richard

AU - Van Besien, Koen

AU - Andersson, Borje

AU - Korbling, Martin

PY - 1996/12/27

Y1 - 1996/12/27

N2 - We have evaluated the use of blood stem cell grafts for rapid hematopoietic recovery and tacrolimus (FK506) as GVHD prophylaxis to reduce early mortality after allogeneic transplantation. Eighty-five adults with advanced leukemia received high-dose thiotepa, busulfan, and cyclophosphamide as a preparative regimen in a prospective Phase II study. All donors were HLA-matched and related. Marrow (BMT) was used for 44 patients and filgrastim-mobilized blood stem cells (SCT) for 41 patients. GVHD prophylaxis consisted of cyclosporine (CsA) or FK506 with methotrexate (MTX) or methylprednisolone (MP). The median time to neutrophil recovery was earlier after SCT than after BMT (day 10 vs. 17, P

AB - We have evaluated the use of blood stem cell grafts for rapid hematopoietic recovery and tacrolimus (FK506) as GVHD prophylaxis to reduce early mortality after allogeneic transplantation. Eighty-five adults with advanced leukemia received high-dose thiotepa, busulfan, and cyclophosphamide as a preparative regimen in a prospective Phase II study. All donors were HLA-matched and related. Marrow (BMT) was used for 44 patients and filgrastim-mobilized blood stem cells (SCT) for 41 patients. GVHD prophylaxis consisted of cyclosporine (CsA) or FK506 with methotrexate (MTX) or methylprednisolone (MP). The median time to neutrophil recovery was earlier after SCT than after BMT (day 10 vs. 17, P

UR - http://www.scopus.com/inward/record.url?scp=8044231318&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=8044231318&partnerID=8YFLogxK

U2 - 10.1097/00007890-199612270-00022

DO - 10.1097/00007890-199612270-00022

M3 - Article

C2 - 8990368

AN - SCOPUS:8044231318

VL - 62

SP - 1806

EP - 1810

JO - Transplantation

JF - Transplantation

SN - 0041-1337

IS - 12

ER -